Seagen antibody-drug conjugate patent suffers dual defeats on appeal in US
A patent owned by Seagen was declared anticipated Tuesday by the same anti-cancer treatment it accused of infringement in 2020. The US Court of Appeals for the Federal Circuit not only...To view the full article, register now.
Already a subscriber? Click here to view full article